UroGen Pharma Ltd. (URGN) Operating cash flow 2016–2025
UroGen Pharma Ltd. (URGN) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$162.4MFY2025 · since FY2016: $4.2M → -$162.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$162.4M | -67.9% |
| FY2024 | -$96.8M | -26.7% |
| FY2023 | -$76.4M | +12.8% |
| FY2022 | -$87.6M | -3.1% |
| FY2021 | -$84.9M | +19.8% |
| FY2020 | -$105.9M | -49.1% |
| FY2019 | -$71.0M | -90.2% |
| FY2018 | -$37.3M | -290.2% |
| FY2017 | -$9.6M | -328.4% |
| FY2016 | $4.2M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More URGN financial trends
URGN RevenueURGN Net incomeURGN Net marginURGN Gross profitURGN Gross marginURGN Operating incomeURGN Operating marginURGN Free cash flowURGN Capital expendituresURGN Return on equityURGN Stock buybacksURGN Dividends paidURGN Total assetsURGN Total liabilitiesURGN Shareholders’ equityURGN overview →